- Home
- VERA
as 07-26-2024 4:00pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 2.0B | IPO Year: | 2021 |
| Target Price: | $42.86 | AVG Volume (30 days): | 592.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.24 - $50.78 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | May 15 '24 | Sell | $43.03 | 2,500 | $107,572.50 | 51,206 | SEC Form 4 |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | May 15 '24 | Sell | $42.22 | 18,151 | $766,317.07 | 51,206 | SEC Form 4 |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | May 15 '24 | Sell | $42.68 | 1,965 | $83,866.20 | 51,206 | SEC Form 4 |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | May 15 '24 | Sell | $42.17 | 8,221 | $346,679.57 | 53,171 | SEC Form 4 |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | Apr 10 '24 | Sell | $40.00 | 5,714 | $228,560.00 | 53,171 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.05 | 69,831 | $2,796,801.38 | 96,334 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.65 | 10,988 | $424,708.18 | 85,346 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.13 | 11,648 | $444,080.00 | 73,698 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.25 | 7,361 | $288,926.61 | 66,337 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.20 | 78 | $2,979.21 | 257 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.22 | 80 | $3,137.36 | 177 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.06 | 177 | $7,090.27 | 0 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.22 | 387 | $14,792.69 | 1,233 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.19 | 366 | $14,341.71 | 867 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.06 | 867 | $34,731.15 | 0 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.22 | 672 | $25,685.86 | 2,144 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.19 | 639 | $25,044.33 | 1,505 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.06 | 1,505 | $60,285.79 | 0 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.23 | 201 | $7,684.43 | 656 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.20 | 203 | $7,956.99 | 453 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.05 | 453 | $18,144.46 | 0 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $38.22 | 3,112 | $118,949.98 | 14,909 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $39.19 | 2,944 | $115,384.19 | 11,965 | SEC Form 4 |
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Apr 3 '24 | Sell | $40.06 | 6,965 | $278,997.01 | 5,000 | SEC Form 4 |
| Katabi Maha | VERA | Director | Mar 21 '24 | Sell | $43.00 | 32,756 | $1,408,508.00 | 3,595,690 | SEC Form 4 |
Latest Vera Therapeutics Inc. News
VERA Breaking Stock News: Dive into VERA Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Vera Therapeutics Appoints David Johnson as Chief Operating Officer
GlobeNewswire
a month ago
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
GlobeNewswire
a month ago
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
GlobeNewswire
2 months ago
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment
GlobeNewswire
2 months ago
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
Compare VERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.